Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia.
OBJECTIVE
The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP).


METHODS
A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemo therapy between January 2002 and December 2013 were retrospectively reviewed.


RESULTS
The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and 1-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%.


CONCLUSIONS
The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Naohiro
N
Watanabe
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan siniho@east.ncc.go.jp.
Seiji
S
Niho
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Keisuke
K
Kirita
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Shigeki
S
Umemura
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Shingo
S
Matsumoto
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kiyotaka
K
Yoh
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hironobu
H
Ohmatsu
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Koichi
K
Goto
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000150:complications*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine
Acute exacerbation; cisplatin; interstitial pneumonia; non-small cell lung cancer; vinorelbine